Terms: = Skin cancer AND MAF, MGC71685, 4094, ENSG00000178573 AND Prognosis
4 results:
1. The clinicopathological impact of tumor-associated macrophages in patients with cutaneous malignant melanoma.
Asai Y; Yanagawa N; Osakabe M; Yamada N; Sugimoto R; Sato A; Ito K; Koike Y; Tanji T; Sakuraba M; Sato T; Sugai T
J Surg Oncol; 2024 Feb; 129(2):381-391. PubMed ID: 37916518
[TBL] [Abstract] [Full Text] [Related]
2. Development of a Macrophage-Related Risk Model for Metastatic Melanoma.
Li Z; Zhang X; Jin Q; Zhang Q; Yue Q; Fujimoto M; Jin G
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762054
[TBL] [Abstract] [Full Text] [Related]
3. Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.
Mattila KE; Mäkelä S; Kytölä S; Andersson E; Vihinen P; Ramadan S; Skyttä T; Tiainen L; Vuoristo MS; Tyynelä-Korhonen K; Koivunen J; Kohtamäki L; Aittomäki K; Hernberg M
Acta Oncol; 2022 Oct; 61(10):1263-1267. PubMed ID: 36307938
[TBL] [Abstract] [Full Text] [Related]
4. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.
Usmani SZ; Heuck C; Mitchell A; Szymonifka J; Nair B; Hoering A; Alsayed Y; Waheed S; Haider S; Restrepo A; Van Rhee F; Crowley J; Barlogie B
Haematologica; 2012 Nov; 97(11):1761-7. PubMed ID: 22689675
[TBL] [Abstract] [Full Text] [Related]
